DE60214019D1 - Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren - Google Patents

Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren

Info

Publication number
DE60214019D1
DE60214019D1 DE60214019T DE60214019T DE60214019D1 DE 60214019 D1 DE60214019 D1 DE 60214019D1 DE 60214019 T DE60214019 T DE 60214019T DE 60214019 T DE60214019 T DE 60214019T DE 60214019 D1 DE60214019 D1 DE 60214019D1
Authority
DE
Germany
Prior art keywords
nitrogen
containing heterocycles
raf inhibitors
raf
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60214019T
Other languages
English (en)
Other versions
DE60214019T2 (de
Inventor
David Kenneth Dean
Antoinette Naylor
Andrew Kenneth Takle
David Matthew Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of DE60214019D1 publication Critical patent/DE60214019D1/de
Publication of DE60214019T2 publication Critical patent/DE60214019T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60214019T 2001-09-05 2002-09-05 Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren Expired - Fee Related DE60214019T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0121494.9A GB0121494D0 (en) 2001-09-05 2001-09-05 Compounds
GB0121494 2001-09-05
PCT/EP2002/009942 WO2003022836A1 (en) 2001-09-05 2002-09-05 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors

Publications (2)

Publication Number Publication Date
DE60214019D1 true DE60214019D1 (de) 2006-09-28
DE60214019T2 DE60214019T2 (de) 2007-01-18

Family

ID=9921562

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60214019T Expired - Fee Related DE60214019T2 (de) 2001-09-05 2002-09-05 Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren

Country Status (8)

Country Link
US (1) US7297693B2 (de)
EP (1) EP1432702B1 (de)
JP (1) JP2005505563A (de)
AT (1) ATE336489T1 (de)
DE (1) DE60214019T2 (de)
ES (1) ES2268110T3 (de)
GB (1) GB0121494D0 (de)
WO (1) WO2003022836A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037835A1 (en) 1999-11-22 2001-05-31 Smithkline Beecham Plc. Novel compounds
EP1263753B1 (de) * 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivate als raf kinase inhibitoren
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
JP2005504793A (ja) * 2001-09-05 2005-02-17 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｒａｆキナーゼ阻害剤としてのヘテロサイクルカルボキサミド誘導体
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
CN101808994B (zh) 2007-07-17 2013-05-15 普莱希科公司 用于激酶调节的化合物和方法以及其适应症
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
EP2399921B1 (de) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclische verbindung und deren verwendung
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126852B1 (de) 1998-11-04 2004-01-21 SmithKline Beecham Corporation Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
JP2005505563A (ja) 2005-02-24
WO2003022836A1 (en) 2003-03-20
US7297693B2 (en) 2007-11-20
US20040209883A1 (en) 2004-10-21
DE60214019T2 (de) 2007-01-18
EP1432702A1 (de) 2004-06-30
GB0121494D0 (en) 2001-10-24
EP1432702B1 (de) 2006-08-16
ES2268110T3 (es) 2007-03-16
ATE336489T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
ATE300529T1 (de) Imidazolderivate als raf-kinase-inhibitoren
GB0121490D0 (en) Ciompounds
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
DE602005009318D1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
GB0402137D0 (en) Novel compounds
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
EA200970738A1 (ru) Ингибиторы активности akt
TW200801008A (en) Protein kinase inhibitors
IL180147A0 (en) N - (1 - (1 - benzyl - 4 - phenyl - 1h-imidazol - 2 - yl) - 2,2 - dymethylpropyl) benzamide derivatives and related compounds as kinesin spidle protein (ksp) inhibitors for the treatment of cancer
DE60319158D1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
DE50310516D1 (de) Fredericamycin-derivate
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
ATE428712T1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
DE60214019D1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
DE602004004259D1 (de) (6-(PHENOXY)-PYRIDOi3,4-DöPYRIMIDIN-2-YL)-AMIN DERIVATE ALS P38 KINASE INHIBITOREN ZUR BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN WIE RHEUMATOIDER ARTHRITIS
DE50308230D1 (de) Pyrazoloisoquinolinenderivaten zur inhibierung von nfkappab-induzierende kinase
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
WO2003106970A3 (en) P27 INHIBITOR USED IN THE PREVENTION OF CELL MIGRATION

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee